NHSA welcomes multimillion pound clinical trials investment
New investment in UK clinical research welcomed by NHSA Chief Executive
2nd September 2024
Following the government’s announcement of a joint public-private investment programme worth up to £400million to strengthen clinical trials and improve medicines manufacturing in the UK, the NHSA’s Chief Executive, Hannah Davies, has welcomed the ‘much-needed’ investment.
Hannah said: “We are delighted to see the importance of health research recognised with this much-needed investment, which will not only help to improve patient care and health outcomes but also bring economic benefits to the UK health and life sciences sector.
“Our analysis of health research spending exposed the persisting regional imbalance in health research funding, with the North losing out on millions of pounds compared to the Greater South East. We hope that this new investment will be spread fairly across the UK so the North’s health research excellence, and proven capabilities in delivering clinical trials, have the opportunity to thrive and compete on a global scale.”
Related News Articles
Survival rates for incurable larynx cancer investigated for first time
First-of-its-kind research looking at survival rates for patients with incurable larynx cancer has been published this week.
Read the articleNHSA CEO responds to the Autumn Budget
Northern Health Science Alliance CEO responds to today's Autumn Budget
Read the articleRenowned health research leaders join NHSA Board
The Northern Health Science Alliance (NHSA) has welcomed two health research experts to its board, strengthening the governance of the leading health and life sciences organisation.
Read the article